All IndicationsRare & Genetic DiseasesPhase 3Phase 3Phase 2Phase 2Phase 2
🧬
Sickle Cell Disease
4
Companies
6
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
VRTX
Vertex Pharmaceuticals Incorporated
Casgevy
BreakthroughFast TrackOrphan Drug
AGIO
Agios Pharmaceuticals, Inc.
Mitapivat
BEAM
Beam Therapeutics Inc.
BEAM-101
HSCSW
HeartSciences Inc.
r-ATG
AGIO
Agios Pharmaceuticals, Inc.
Tebapivat Matched Placebo
AGIO
Agios Pharmaceuticals
Tebapivat
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | Casgevy | Phase 3 | BTFTOD | — | — |
| AGIO Agios Pharmaceuticals, Inc. | Mitapivat | Phase 3 | — | — | — |
| BEAM Beam Therapeutics Inc. | BEAM-101 | Phase 2 | — | — | — |
| HSCSW HeartSciences Inc. | r-ATG | Phase 2 | — | — | — |
| AGIO Agios Pharmaceuticals, Inc. | Tebapivat Matched Placebo | Phase 2 | — | — | — |
| AGIO Agios Pharmaceuticals | Tebapivat | — | — | — | — |
Development Stage Distribution
Unknown
1
Phase 3
2
Phase 2
3
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.